Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 7/20 | 0.38 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.38 |
| ▸ | TEK | Q02763 | 1/20 | 0.38 |
| ▸ | BTK | Q06187 | 2/20 | 0.38 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.38 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 3/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.35 |
| ▸ | CIT | O14578 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | MET | P08581 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15053476 | 0.92 | KDR (0.39) | KDREPHB4TEKBTKIRAK4 | |
| SCHEMBL3707580 | 0.92 | MEN1 (0.44) | KDRBTKMAP3K7KDM4EMAPT | |
| SCHEMBL3701262 | 0.92 | KDM4E (0.42) | KDRBTKKDM4EMAPTMEN1 | |
| SCHEMBL3707818 | 0.91 | ALDH1A1 (0.46) | KDREPHB4KDM4EMAPTMEN1 | |
| SCHEMBL3705933 | 0.91 | KMT2A (0.39) | KDRBTKMAP3K7KDM4EMAPT | |
| SCHEMBL3699717 | 0.90 | BTK (0.44) | KDRBTKMAP3K7KDM4EMAPT | |
| Hydrochloric Acid SCHEMBL3699244 | 0.90 | ALDH1A1 (0.45) | KDREPHB4KDM4EMAPTMEN1 | |
| SCHEMBL3706455 | 0.89 | HTR1A (0.46) | KDREPHB4TEKIRAK4KDM4E | |
| SCHEMBL3709216 | 0.88 | BRAF (0.38) | KDRBTKMAP3K7MET | |
| SCHEMBL3703979 | 0.86 | STING1 (0.42) | BTKMAP3K7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8648086-B2 | 5,6-bicyclic heteroaryl-containing urea compounds as kinase inhibitors | ASCEPION PHARMACEUTICALS, INC. (CN) | 2014-02-11 | — | — | US | claimed |
| US-20120122895-A1 | 5,6-BICYCLIC HETEROARYL-CONTAINING UREA COMPOUNDS AS KINASE INHIBITORS | JIANG, SHAN | 2012-05-17 | — | — | US | claimed |
| US-8648086-B2 | 5,6-bicyclic heteroaryl-containing urea compounds as kinase inhibitors | ASCEPION PHARMACEUTICALS, INC. (CN) | 2014-02-11 | — | — | US | disclosed |
| US-20120122895-A1 | 5,6-BICYCLIC HETEROARYL-CONTAINING UREA COMPOUNDS AS KINASE INHIBITORS | JIANG, SHAN | 2012-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122895-A1 | 5,6-BICYCLIC HETEROARYL-CONTAINING UREA COMPOUNDS AS KINASE INHIBITORS | FLT3, CSF1R, EPHA2 | KDR 9/4885EPHB4 33/4885TEK 23/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.